182 related articles for article (PubMed ID: 20332676)
41. [Three cases of hepatocellular carcinoma without distant metastasis effectively treated by sorafenib].
Takeda Y; Nakahira S; Takeno A; Suzuki R; Nakata K; Okishiro M; Egawa C; Okamura S; Miki H; Kato T; Takatsuka Y; Tamura S
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2496-8. PubMed ID: 22202425
[TBL] [Abstract][Full Text] [Related]
42. Intra-arterial infusion of chemotherapy for advanced hepatocellular carcinoma: an Asian perspective.
Chan SL; Johnson P
Asia Pac J Clin Oncol; 2012 Jun; 8(2):111-4. PubMed ID: 22524569
[No Abstract] [Full Text] [Related]
43. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.
Strumberg D
Drugs Today (Barc); 2005 Dec; 41(12):773-84. PubMed ID: 16474853
[TBL] [Abstract][Full Text] [Related]
44. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
Kawaoka T; Aikata H; Hyogo H; Morio R; Morio K; Hatooka M; Fukuhara T; Kobayashi T; Naeshiro N; Miyaki D; Hiramatsu A; Imamura M; Kawakami Y; Takahashi S; Waki K; Tsuji K; Kohno H; Kohno H; Moriya T; Chayama K
J Dig Dis; 2015 Sep; 16(9):505-12. PubMed ID: 26121102
[TBL] [Abstract][Full Text] [Related]
45. [Targeted therapies in hepatocellular carcinoma].
Bouattour M; Marijon H; Dreyer C; Faivre S; Raymond E
Presse Med; 2010; 39(7-8):753-64. PubMed ID: 20378303
[TBL] [Abstract][Full Text] [Related]
46. Current status of hepatocellular carcinoma treatment in Japan: practical use of sorafenib (Nexavar®).
Kokudo N; Nakajima J; Hatano E; Numata K
Clin Drug Investig; 2012 Aug; 32 Suppl 2():25-35. PubMed ID: 22873625
[TBL] [Abstract][Full Text] [Related]
47. Targeted therapies: Role of sorafenib in HCC patients with compromised liver function.
Di Maio M; Daniele B; Perrone F
Nat Rev Clin Oncol; 2009 Sep; 6(9):505-6. PubMed ID: 19707242
[No Abstract] [Full Text] [Related]
48. Medical treatments: in association or alone, their roles and their future perspectives: the Western experience.
Reig M; Bruix J
J Hepatobiliary Pancreat Sci; 2010 Jul; 17(4):420-1. PubMed ID: 19890601
[TBL] [Abstract][Full Text] [Related]
49. [Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].
Reig M; Matilla A; Bustamante J; Castells L; de La Mata M; Delgado M; Moreno JM; Forner A; Varela M
Gastroenterol Hepatol; 2010 Dec; 33(10):741-52. PubMed ID: 20851505
[No Abstract] [Full Text] [Related]
50. Sorafenib in hepatocellular carcinoma: separating the hype from the hope.
Kelley RK; Venook AP
J Clin Oncol; 2008 Dec; 26(36):5845-8. PubMed ID: 19029408
[No Abstract] [Full Text] [Related]
51. A single-institute experience with sorafenib in untreated and previously treated patients with advanced hepatocellular carcinoma.
Balsom SM; Li X; Trolli E; Rose J; Bloomston M; Patel T; Bekaii-Saab TS
Oncology; 2010; 78(3-4):210-2. PubMed ID: 20424492
[TBL] [Abstract][Full Text] [Related]
52. Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
Yau T; Pang R; Chan P; Poon RT
Expert Opin Pharmacother; 2010 Sep; 11(13):2187-98. PubMed ID: 20707757
[TBL] [Abstract][Full Text] [Related]
53. Chemotherapy for hepatocellular carcinoma: current status and future perspectives.
Ikeda M; Morizane C; Ueno M; Okusaka T; Ishii H; Furuse J
Jpn J Clin Oncol; 2018 Feb; 48(2):103-114. PubMed ID: 29253194
[TBL] [Abstract][Full Text] [Related]
54. Hepatocellular carcinoma: The beginning of a long journey.
Cascinu S
Dig Liver Dis; 2009 Oct; 41(10):707-8. PubMed ID: 19699696
[No Abstract] [Full Text] [Related]
55. Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice?
Sacco R; Bargellini I; Ginanni B; Bertini M; Faggioni L; Federici G; Romano A; Bertoni M; Metrangolo S; Altomare E; Parisi G; Tumino E; Scaramuzzino A; Bresci G; Bartolozzi C
Expert Rev Anticancer Ther; 2012 Jul; 12(7):869-75. PubMed ID: 22845401
[TBL] [Abstract][Full Text] [Related]
56. Potential impact of sorafenib on the survival benefit of liver transplantation for hepatocellular carcinoma.
Vitale A; Lombardi G; Ramirez Morales R; Cillo U
Dig Liver Dis; 2012 May; 44(5):361-2. PubMed ID: 22424640
[No Abstract] [Full Text] [Related]
57. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy.
Saab S; McTigue M; Finn RS; Busuttil RW
Exp Clin Transplant; 2010 Dec; 8(4):307-13. PubMed ID: 21143097
[TBL] [Abstract][Full Text] [Related]
58. [Palliative management of hepatocarcinoma with sorafenib (Nexavar). Results of the SHARP study (sorafenib hepatocarcinoma assessment randomized protocol trial)].
Detry O; Delwaide J; De Roover A; Meunier P; Van Daele D; Lamproye A; Honoré P; Polus M
Rev Med Liege; 2009 Mar; 64(3):168-70. PubMed ID: 19418937
[TBL] [Abstract][Full Text] [Related]
59. Current status of hepatocellular carcinoma treatment in Japan: hepatic arterial infusion chemotherapy.
Yamashita T
Clin Drug Investig; 2012 Aug; 32 Suppl 2():15-23. PubMed ID: 22873624
[TBL] [Abstract][Full Text] [Related]
60. Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment.
Wörns MA; Schuchmann M; Düber C; Otto G; Galle PR; Weinmann A
Oncology; 2010; 79(1-2):85-92. PubMed ID: 21071995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
